首页> 外文期刊>The Prostate >Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers.
【24h】

Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers.

机译:人激肽释放酶10(KLK10)基因中单核苷酸多态性的鉴定及其与前列腺癌,乳腺癌,睾丸癌和卵巢癌的关系。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: The KLK10 gene (also known as the normal epithelial cell-specific 1 gene) is a member of the expanded human kallikrein gene family. Recently, it has been reported that KLK10 is a tumor suppressor gene and that its expression is downregulated in various forms of cancer and cancer cell lines. KLK10 is also upregulated in ovarian cancer. We thus hypothesized that the KLK10 gene may be a target for mutations in various cancers. METHODS: We sequenced the five coding exons of the KLK10 gene using genomic DNA from various tumors, normal tissues, and blood, by PCR amplification and automated sequencing. RESULTS: In none of the tumor-derived DNAs, we identified somatic mutations that could inactivate this gene. However, we identified a prevalent germline single nucleotide variation at codon 50 (exon 3) of this gene [GCC (alanine) to TCC (serine)]. The GCC genotype was less prevalent in prostatic cancer patients in comparison to control subjects (P = 0.027) but no differences were seen with testicular, ovarian, and breast cancer. We also identified four genetic variations in exon 4, at codons106 [GGC (glycine) to GGA (glycine)], codon 112 [ACG (threonine) to ACC (threonine)], codon 141 [CTA (leucine) to CTG (leucine)], and at codon 149 [CCG (proline) to CTG (leucine)]. None of these variations was significantly different between normal subjects and cancer groups. CONCLUSIONS: We found no evidence for somatic mutations of the KLK10 gene in cancers of the prostate, breast, ovary, and testis. The single nucleotide variation at codon 50 appears to be associated with prostate cancer risk.
机译:背景:KLK10基因(也称为正常上皮细胞特异性1基因)是扩展的人类激肽释放酶基因家族的成员。最近,已经报道KLK10是肿瘤抑制基因,并且其表达在各种形式的癌症和癌细胞系中被下调。 KLK10在卵巢癌中也上调。因此,我们假设KLK10基因可能是各种癌症突变的靶标。方法:我们通过PCR扩增和自动测序,使用来自各种肿瘤,正常组织和血液的基因组DNA对KLK10基因的五个编码外显子进行了测序。结果:在没有一个肿瘤来源的DNA中,我们鉴定出可以使该基因失活的体细胞突变。但是,我们在该基因的密码子50(第3外显子)[GCC(丙氨酸)至TCC(丝氨酸)]中鉴定了普遍的种系单核苷酸变异。与对照组相比,前列腺癌患者的GCC基因型较少(P = 0.027),但在睾丸癌,卵巢癌和乳腺癌中没有发现差异。我们还确定了第4外显子的四个遗传变异,密码子为106 [GGC(甘氨酸)至GGA(甘氨酸)],密码子112 [ACG(苏氨酸)至ACC(苏氨酸)],密码子141 [CTA(亮氨酸)至CTG(亮氨酸)。 ],密码子为149 [CCG(脯氨酸)至CTG(亮氨酸)]。这些变异在正常受试者和癌症组之间均无显着差异。结论:我们没有发现在前列腺癌,乳腺癌,卵巢癌和睾丸癌中KLK10基因发生体细胞突变的证据。密码子50处的单核苷酸变异似乎与前列腺癌风险相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号